 CAMBRIDGE, Mass., June 27, 2022 GLOBE NEWSWIRE -- Beam Therapeutics Inc. Nasdaq: BEAM, a biotechnology company developing precision genetic medicines through base editing, today announced that new research highlighting the companys internal efforts to develop improved transplant conditioning regimens for patients with sickle cell disease SCD undergoing hematopoietic stem cell transplantation HSCT will be presented today, June 27, 2022, at 4:00 p.m. CEST at the Federation of American Societies for Experimental Biology FASEB Genome Engineering Conference by Nicole Gaudelli, Ph.D., director, head of gene editing at Beam. The conference is being held from June 26-30, 2022, in Lisbon, Portugal. 